Skip to main content
MedPathMedPath Home
Clinical Trials/JPRN-jRCTs051180214
JPRN-jRCTs051180214
Recruiting
未知

The usefulness of brain amyloid image using flutemetamol and glucose metabolism for the neurogenerative disease - The usefulness of brain amyloid image using flutemetamol and glucose metabolism for the neurogenerative disease

Itoh Yoshiaki0 sites100 target enrollmentMarch 27, 2019
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Itoh Yoshiaki
Enrollment
100
Status
Recruiting
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 27, 2019
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Itoh Yoshiaki

Eligibility Criteria

Inclusion Criteria

  • •Healthy control
  • •1\. Ages 20 and over
  • •2\. Written informed consent
  • •1\. Diagnosed as neurogenerative disease related to tau protain (Alzheimer's disease, Dementia with Lewy Bodies, Frontotemporal lobar degeneration, Parkinson's syndrome) by clinical symptom, Neurological findings, MRI and cognitive function test.
  • •2\. Written informed consent

Exclusion Criteria

  • •Healthy control
  • •1\. A person who has brain disease (Parkinson's disease, dementia related disease, etc.)
  • •2\. A person who has serious disease complications or who has a history of these and who is considered as inappropriate by researcher.
  • •3\. Pregnant, unwilling to practice contraception during the study, or lactating female.
  • •4\. Participated in nuclear medicine examination within 6 months.
  • •5\. Claustrophobia
  • •6\. Judged inappropriate as subject by investigator.
  • •1\. A person who is complicated by brain disease other than the disease concerned (including an obvious history of cerebral infarction) and taking a drug that effects on the central nervous system
  • •2\. A person who has serious disease complications or has a history of these and is judged to be unsuitable as a subject of this research by a doctor who is a researcher etc.
  • •3\. Pregnant, unwilling to practice contraception during the study, or lactating female.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
Determine the value of the compound [18F]-AV45, which is usable for visualization of the build-up of the amyloid protein in brains of memory clinic patients, in making a diagnosis in patients of the memory outpatient clinic.The total number of inclusion in this study is 170 subjects140 patients (including Alzheimer’s disease (AD) patients, patients with mild cognitive impairment (MCI), patients with subjective memory complaints (SMC), patients with other neurodegenerative diseases and 30 cognitively normal volunteers.Therapeutic area: Psychiatry and Psychology [F] - Mental Disorders [F03]
EUCTR2012-001599-12-NLVU University Medical Center (VUmc)170
Completed
Not Applicable
[18F]-flutemetamol amyloid imaging along the continuum from normal cognitive status to Alzheimer's disease dementia.
JPRN-jRCT1091220124Shizuo Hatashita120
Completed
Phase 4
The clinical prognostic value of amyloid imaging with [18F]AV-45 in a subjects with subjective complaintsAlzheimer's Diseasedementia of the Alzheimer type1002930510012272
NL-OMON47767Vrije Universiteit Medisch Centrum280
Completed
Not Applicable
Amyloid imaging study using positron emission tomography with [F-18]FACT for dementiaDementia
JPRN-UMIN000001420ational Institute of Radiological Sciences60
Enrolling By Invitation
Phase 4
Imaging of Brain Amyloid Plaques in the Aging PopulationAlzheimer's DiseaseDementia With Lewy BodiesFrontotemporal DementiaVascular Dementia
NCT00950430Mayo Clinic8,000